California's AB 1965 Expands Cannabis Testing Transparency for Patients

Medical Marijuana Card California announced that patients in California will gain enhanced access to product testing information under Assembly Bill 1965, a newly enacted law signed on September 27, 2026. The legislation amends Sections 26070, 26100, and 26104 of the California Business and Professions Code, focusing on cannabis laboratory standards, product transparency, and regulatory oversight.

The law expands the authority of the California Department of Cannabis Control (DCC) to oversee cannabis product testing and establishes requirements for retailers to provide customers with laboratory testing documentation. Although the law does not change medical marijuana recommendation eligibility, its product transparency provisions are relevant to patients purchasing cannabis from licensed retailers.

California already requires regulated cannabis products to undergo laboratory testing before entering the licensed retail market. According to the DCC's official cannabis testing guidance, licensed laboratories examine cannabis products for cannabinoid concentrations, including THC and CBD; residual pesticides and processing chemicals; heavy metals and microbial impurities; mycotoxins and other regulated contaminants; and moisture content and foreign materials. Testing laboratories document their findings through Certificates of Analysis (COAs), which identify testing results and whether a product batch meets applicable requirements.

Starting January 1, 2027, AB 1965 will mandate that licensed retailers and other businesses authorized for retail cannabis sales provide the Certificate of Analysis upon customer request. This initiative offers medical cannabis patients improved access to laboratory information about potential products. A COA can help consumers review cannabinoid concentrations and testing results for substances such as pesticides, heavy metals, and microbial contaminants. However, a laboratory report does not establish whether a particular cannabis product is medically appropriate for an individual patient.

AB 1965 also authorizes the Department of Cannabis Control to obtain or access cannabis products offered for retail sale for independent, off-the-shelf laboratory testing. The law mandates performance testing to ensure consistency across facilities, including retesting and laboratory procedure improvements. These provisions build upon California's existing cannabis quality assurance framework. The DCC's cannabis laws and regulations provide further information about the regulatory requirements governing licensed cannabis businesses.

AB 1965 primarily concerns cannabis product testing and retail transparency. It does not introduce new medical marijuana card eligibility requirements or replace the physician recommendation process. As patients review the upcoming testing requirements, Medical Marijuana Card California emphasizes the importance of understanding the difference between medical cannabis recommendations, county-issued identification cards, and product testing regulations. Under California's existing system, eligible patients may obtain medical cannabis recommendations from qualified physicians. The state's Medical Marijuana Identification Card Program is a separate, voluntary program administered through county health departments. According to the California Department of Public Health's official MMIC guidance, applicants seeking a county-issued medical marijuana identification card must provide documentation that includes a physician's medical recommendation, proof of identity, and proof of residency.

Patients preparing for the upcoming requirements can take several practical steps: understand laboratory reports by learning how Certificates of Analysis document cannabinoid concentrations and regulated contaminant testing; verify retailer licensing before purchasing cannabis products by using the DCC's official license search to confirm that a cannabis retailer holds an appropriate state license; request product testing information once the new requirement takes effect; review medical documentation to keep applicable physician recommendations and other required documentation current; and follow official regulatory updates from the California Department of Cannabis Control and California Department of Public Health.

The new requirements are designed to strengthen product testing oversight and transparency. They should not be interpreted as changes to individual medical eligibility or physician certification standards. This advisory provides general educational information, not medical or legal advice. Patients should verify current requirements through California government agencies and consult qualified healthcare or legal professionals when appropriate.